Prostate Cancer: KOL Insight 2016

NEW YORK, Nov. 17, 2017 /PRNewswire/ --

Read the full report: https://www.reportlinker.com/p04833574

Good news for late-stage prostate cancer patients: a host of new therapies are in the pipeline, indications for mainstay drug classes are expanding, and personalized treatment may be just around the corner. Find out how doctors and manufacturers are dealing with a fast-evolving treatment algorithm and more intense competition in KOL Insight: Prostate Cancer.

Twelve North American and European KOLs' weigh in on the near-term outlook for 5 marketed prostate cancer treatments and 14 more currently in the pipeline. Learn whether hormonal therapies will move into earlier settings, whether bone-targeted therapies will see wider use in combination, whether new immunotherapies will outperform first-generation predecessors, whether PARP inhibitors offer real hope for personalized medicine, and more.

"We have to focus now on how to better select our patients and to better understand the disease and make treatment strategies and treatment sequences really adapted on a per patient basis in terms of selection. I think that is the key."
- Andrew J Armstrong. Associate Professor of Medicine and Surgery and Medical Oncologist at Duke University and the Duke Cancer Institute, Durham, NC.
- Tomasz M Beer. Professor, Division of Hematology and Medical Oncology and Deputy Director, Oregon Health & Science University Knight Cancer Institute, Portland, OR.
- David E Crawford. Professor of Surgery, Urology, and Radiation Oncology, and head of the Section of Urologic Oncology at the University of Colorado, Aurora, CO.
- Daniel P Petrylak. Professor of Medicine (Medical Oncology) and Urology at Yale School of Medicine, New Haven, CT.
- Chris Parker. Senior Lecturer and Honorary Consultant in Clinical Oncology and Prostate Cancer Translational Research at The Institute of Cancer Research and The Royal Marsden, London, UK.

Top Takeaways
- Kick-starting personalized medicine: when it comes to personalizing treatment, prostate cancer lags behind other malignancies. Now KOLs think that Lynparza and other PARP inhibitors could change that. What's driving their optimism?
- Hormonal therapies to see earlier use: Next-generation hormonal therapies like Xtandi, Zytiga, and apalutamide are moving up the treatment algorithm. What are the most promising indications for these drugs, and what effect do KOLs expect to see on overall survival (OS)?
- Key differentiators needed: With so many Phase III trials of hormonal therapies ongoing, KOLs anticipate stiff competition. What are the three key factors that will do the most to differentiate new market entrants?
- Potential for Bone-Targeted Therapy Combinations: A handful of clinical trials evaluating combinations of bone-targeted therapies and other agents are underway. Could the results push bone-targeted therapies up the treatment algorithm?
- Outlook unclear for new immunotherapies: An underwhelming performance by Provenge has lowered expectations for vaccines and immunotherapies in prostate cancer treatment. Will Prostvac and other new options in the pipeline fare better?
- Earlier use of chemotherapy: In the wake of the STAMPEDE and CHAARTED trials, chemotherapy is being used earlier in the treatment algorithm. Do KOLs expect this trend to continue?
- Endpoint shuffle: KOLs have concerns about continued use of OS as an endpoint for clinical trials, but what's the alternative? Do they consider metastases free survival (MFS) to be a valid predictor of OS and an approvable endpoint?
- Future of the treatment algorithm hinges on key trials: Get KOLs Thoughts on over 20 ongoing or recently completed clinical trials including EMBARK, PROSPER, PRESIDE, ENZAMET, ENZARAD, PEACE 1, SPARTAN, ATLAS, TITAN, TOPARP-A, and others.

Read the full report: https://www.reportlinker.com/p04833574

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

Related Links

http://www.reportlinker.com